The field of multiple sclerosis (MS) is evolving at a rapid pace from disease modifying therapies (DMTs) to diagnostic/monitoring tools to fundamental principles that shape how clinicians think about the disease. Though such advancements are welcome, they continue to raise new questions about how to optimize management for individual patients. In this program, real clinicians who treat MS pose their most pressing clinical questions to an expert panel. These specialists then provide their best answers through literature and their own clinical experience.
=Consensus Recommendations for Use of p16/Ki67 Dual Staining Cytology in the Management of Individuals Testing Positive for HPV
Strategic Excellence: Mastering the Expanding ATTR-CM Therapeutic Landscape in Pharmacy Practice
Accurate Staging and Determining Resectability in NSCLC
Consolidation Immunotherapy After Concurrent CRT: What Do Real-World Data Show?
Consolidative Immunotherapy Following sCRT vs RT Only in Stage III NSCLC
Chemoradiotherapy Toxicities: How Do They Impact Starting Immunotherapy?
Consolidative Immunotherapy in Unresectable Stage III NSCLC With Oncogenic Drivers
Immunotherapy Approaches in Unresectable Stage III NSCLC: What’s on the Horizon?
Differentiating and Managing Pneumonitis in Unresectable Stage III NSCLC: Case Discussion
Resolving Practice Barriers to Consolidative Immunotherapy in Stage III NSCLC
Optimizing Consolidative Immunotherapy in Unresectable Stage III NSCLC: Case Discussion
Initial BTK Inhibitor-Based Treatment Selection in a Treatment-Naive, Symptomatic, Unfit Older Patient With Comorbidities and High-Risk Cytogenetics
Selection of BTK Inhibitor Following Frontline Chemoimmunotherapy in Older Patients With Comorbidities
Safety and Tolerability of Changing Covalent BTK Inhibitor Treatment in a Patient Intolerant to Ibrutinib or Acalabrutinib
ATTR-CM Management: Pearls From Recent Clinical Trials and Tailoring Therapy
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
Are Two Pathways Better Than One? Experts Discuss the Role of Ang-2/VEGF-A Inhibition in Retinal Vascular Disease
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
The Role of Immunotherapy in the Treatment of Recurrent or Metastatic HNSCC: The Evidence
Current and Emerging Biomarkers of Response to Immunotherapeutic Regimens
Create your
podcast in
minutes
It is Free
RenaissanceOnlineRadio.com
Men in Lead Aprons
Denver Underground
Exercise: Learn To Love (Or At Least Like) It
NASACast Video